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How to lie with (FDA) statistics
The FDA approved 27 new drugs in 2013. Is this a downward
trend? Is it an upward trend? Does it suggest that the
pharmaceutical industry is failing, or that genomics is finally
paying dividends? We revisit Darrell Huff’s 1954 classic How to
Lie with Statistics for insights into these pressing questions.

Fred D. Ledley1
Center for Integration of Science and Industry, Departments of Natural &
Applied Science and Management, Bentley University, Waltham, MA.

The headline of a recent AP story read “The Big Story, New drug approvals from FDA declined in
2013.” Indeed, the FDA approved only 27 New Molecular Entities (NMEs) in 2013, compared to
39 in 2012. This discouraging news was widely reported in mainstream and business media.
The same AP story, however, also quotes FDA officials as saying that “the tally of innovative
medications approved last year is in line with the historical trend.” The official FDA report on
2013 approvals goes into more detail, stating “CDER approved 27 NMEs in 2013, which is similar
to average totals of other years from this time period. For instance, from 2004 through 2012,
CDER has averaged about 26 NME approvals per year. In 2012, CDER approved 39 NMEs, but
this was an unusually high number….” While the headline lamented the lower number of
approvals in 2013, the Associated Press story, in fact, expands on the higher number observed
in recent years, stating that: “Experts attribute the recent uptick to a combination of factors: a
stable, well-funded FDA and a newly established research model among drug makers…” This
view was echoed by a commentary on the web site of the National Venture Capital Association,
extolling the importance of regulatory reforms championed by the Association, which stated:
“…we believe that the upward trend in drug approvals over the past several years has increased
investor confidence in the FDA's review and approval process.”
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So, what happened I 2013? Did the number of new drug approval decline? Was it unchanged?
Or was it evidence of an upward trend?
These conflicting interpretations of the FDA’s data reminded me of Darrell Huff’s classic book
How to Lie with Statistics (W.W. Norton, 1954) and his statement that “The secret language of
statistics, so appealing in a fact-minded culture, is employed to sensationalize, inflate, confuse,
and oversimplify.” Huff’s book illustrated the subjectivity that could be introduced into analysis
by selective data analysis, graphical representation, and the association of correlations with
trends or causation.
For the record, the FDA has reported
historical data on the number of new
drugs (New Chemical Entities and
Biologicals) as shown in the attached
figures. The top panel shows the raw data
with three possible “trends” that could be
inferred from selectively chosen linear
regressions. The first, 1970-2013, might
be interpreted as representing the “postthalidomide” era of drug development.
The second, 1996-2013, might be
interpreted as representing the postPDUFA (Prescription Drug User Fee Act of
1993) era of the FDA; and the others,
2005-2013, or the 2004-2013 time frame
described by the FDA, might be used to
assess recent trends. In the tradition of
“How to Lie with Statistics,” each of these arbitrary analyses provides the basis for empirical,
though not statistically significant, narratives suggesting that drug development trends are
either positive (green) or negative (red).
Fitting more complex equations to the data is not much better. The bottom panel shows the
application of various analytical formulations including linear regression (purple), a 20 year
moving averages (blue), or 4th and 5th order polynomials (orange). The 10 year moving average
is in bold with +/- SD of the residual shaded. Thus, quantitative analysis of drug approval data
alone does not conveniently support either a “declining” or “upward” narrative.
Can anything be learned from the FDA data?

The FDA’s data is seemingly consistent with Jurgen Drews’ 1995 prediction, that the number of
new pharmaceutical products in development at that time was not sufficient to replace the
number coming off patent and sustain continued growth of the biopharmaceutical industry.
While each of the regression models in the bottom panel appear to show growth in the number
of NMEs approved though the 1970s and early 1990s, this trend seems to be absent after 1995.
Less defensible is the statement in the AP release that “FDA drug approvals are watched closely
by analysts as both a barometer of industry innovation and the federal government's efficiency
in reviewing new therapies.” On the surface, it seems innocent to make a causal connection
between innovation in industry, the efficiency of the review process, and the number of NMEs
that result. Indeed, Drews’ concern about the inadequacy of the product pipeline is often
referred to as the “innovation gap.” Yet, as Huff warned, “flaws in assumptions of causality are
not always so easy to spot, especially when the relationship seems to make a lot of sense or
when it pleases a popular prejudice.”
Is the assumption of causality in this instance flawed? We think it might be.
It is recognized that not all technological innovations have a sensible, sustaining effect on
product development. Many technological innovations are incompatible with the capabilities
and conventions of established industries. Such innovations may initially be disruptive to
product development processes and markets until businesses adapt to new technological
requirements and commercial opportunities. Disruptive innovations may require substantial
periods of time to mature before they contribute to the development of competitive products.
In this context, short term changes in number of NME’s reflects only incremental or sustaining
innovations, and not the type of radical and disruptive innovations embodied in genomics and
other “omic” technologies that have emerged in recent decades. In fact, a 2001 report titled
Fruits of Genomics (Lehman Brothers, "The fruits of genomics." New York (2001)) predicted that
genomic innovations in the pharmaceutical industry would initially have a negative impact on
the timelines and cost of drug development. Their model predicted that it would not be until
after 2010 that these innovations would begin to produce increasing numbers of NMEs.
Is there evidence to support the prediction that this “newly established research model” is
finally producing increasing numbers of NMEs? I would suggest that you reread “How to Lie
with Statistics,” then come to your own conclusions.

